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Thomas R. Rogers 
The objectives of this review are: to review the modes of action of currently available antifungal drugs; to define drug 
resistance and discuss the mechanisms by which fungi can develop resistance to antifungal drugs; to consider the 
epidemiological and host factors that contribute to the outcome of antifungal therapy and whether the available in 
vitro susceptibility test methods can reliably predict clinical response; and to assess the overall relevance of drug 
resistance to the outcome of fungal infections.‘Ihe incidence of antifungal drug resistance among pathogens causing 
invasive fungal infections appears to be increasing. In the case of Cundida spp., this may in part be a consequence 
of selective pressure brought about by more intensive antifungal use leading to a ‘pathogen shift’. Non-albicans 
Cundida spp. are more likely to demonstrate reduced susceptibility to fluconazole compared to C. albicans. Suscepti- 
bility breakpoints developed by the National Committee for Clinical Laboratory Standards to test azoles and 
flucytosine against Candida spp. are helpful in guiding therapy. Antifungal drug resistance in yeasts is of clinical 
importance. Increasingly reliable methods of in vitro susceptibility testing can help predict clinical response to 
therapy, but other considerations, including host- and drug-related factors, can also have an important bearing on 
the ultimate outcome of treatment. 
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INTRODUCTION 
Antifungal drugs are widely prescribed both in the 
community and in hospital practice. Despite recent 
developments, there is still a limited repertoire of licensed 
antifungal agents, especially for the treatment of 
invasive fungal infections (IFIs). This is in the face of 
clear evidence of an increase in the incidence of IFIs in 
susceptible patient groups. These include the classical 
immunocompromised populations such as bone marrow 
transplant (BMT) and organ transplant recipients, 
human immunodeficiency virus (HIV)-positive patients 
and, increasingly, patients who are critically ill on high- 
dependency units. The specific indications for antifungal 
drugs in these groups are becoming better delineated, 
and current recommendations are supported in many 
cases by comparative clinical trial data.l” For example, 
in patients with hematological malignancy, antifungal 
drugs are commonly administered for prophylaxis during 
neutropenia, empirical therapy of febrile episodes 
unresponsive to antibiotics, therapy of documented 
infections, and prevention of relapse during further 
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immunosuppression where there is a history of previous 
fungal infection. Over the past two decades, antifungals 
have been widely used in HIV-positive patients for treat- 
ment of oropharyngeal /oesophageal candidiasis (OPC) 
and cryptococcosis. Patients on intensive care units are 
viewed as being at increased risk of invasive candidiasis, 
so that in this setting a role for systemic antifungal 
therapy is rapidly becoming established. It is not 
surprising, then, that the increased use of systemic 
antifungals has had an impact on the epidemiology of 
fungal infections that are frequently seen, and this 
has coincided with the emergence of drug resistance, 
especially in patient groups where the level of use is 
more intensive. Up until the past 5 years, there was no 
widely accepted method for in vitro susceptibility testing 
of fungal pathogens. With the publication by the 
National Committee for Clinical Laboratory Standards 
(NCCLS) in 19974 f o a validated method for deter- 
mining minimum inhibitory concentrations (MICs) of 
widely used antifungals against Candida spp., it became 
possible to evaluate with greater confidence whether in 
vitro susceptibilities correlated with clinical response to 
therapy. In order to understand how these issues impact 
on clinical practice, it is necessary to review the ways in 
which these drugs work, the molecular mechanisms 
involved in resistance, and the relationship between 
increasing use and changing epidemiology of the patho- 
gens involved. 
ANTIFUNGAL DRUGS 
The main classes of antifungal agents, their respective 
members (Table 1) and mechanisms of action5 are as 
follows. 
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Table 1. Main classes of antifungal drugs in clinical use or 
undergoing evaluation* 
Polyenes 
Amphotericin B desoxycholate 
Liposomal amB (‘Ambisome’) 
AmB lipid complex (‘Abelcet’) 
AmB colloidal dispersion (‘Amphocil’) 
Liposomal nystatin (‘Nyotran’)” 
Azoles 
Ketoconazole 
Fluconazole 
ltraconazole 
Voriconazole* 
Posaconazole* 
Ravuconazole* 
Nucytosine 
Allylamines 
Terbinafine 
Echinocandins 
Caspofungin* 
Anidulafungin* 
FK 463* 
Polyenes 
Amphotericin B (amB) and nystatin are the two 
clinically useful members of this group. For many years, 
amB was the only therapeutic agent of value to treat IFI, 
and because of this, together with its broad spectrum of 
activity, it acquired the somewhat dubious title of ‘gold 
standard’ therapy, despite a significant lack of support- 
ing evidence from randomized clinical trials. AmB 
frequently causes nephrotoxicity, and this limits its 
role as an effective agent. The use of nystatin has been 
restricted to topical administration because of even 
greater potential for toxicity. 
Fluconazole has particularly good activity, and 
proven clinical efficacy, against Cundida albicans and 
Cryptococcus neofornaans but no useful activity against 
Aspergillus spp. Itraconazole has a broader spectrum 
than fluconazole but its clinical use has been hampered 
by the lack of a parenteral formulation, which has only 
recently become available, and also because the oral 
solution is poorly tolerated. Voriconazole is a new 
triazole in the advanced stages of clinical evaluation. It 
has a broad spectrum of activity and looks to be particu- 
larly promising for treatment of pulmonary aspergillosis. 
Although the azoles exhibit mainly fungistatic activity in 
vitro, they may be fungicidal under certain circum- 
stances in vivo. 
Flucytosine (5FC) 
The inhibitory effect of the polyenes results from This enters fungal cells through the action of a cytosine 
their interaction with plasma membrane sterols, in permease and is converted by cytosine deaminase into 
particular ergosterol. In the case of amB, this leads to the the active molecules that inhibit both DNA and RNA 
development of pores or channels, which in turn cause synthesis. It is active against both Candida spp and 
leakage of potassium and other cytoplasmic constitu- Cryptococcus neoformans. Its main use is in treatment of 
ents, with cell death as the outcome. There are now three cryptococcosis in combination with amB because of 
commercially available lipid-associated formulations of superior efficacy over amB when given alone.2 It 
amB, and also liposomal nystatin, which is still under- may also be used as combination therapy in invasive 
going clinical evaluation. These have been shown to 
cause significantly less nephrotoxicity than the parent 
desoxycholate formulation. Although they retain the 
same target of action, the mechanism by which each is 
delivered and transfers to its target in the fungal cell has 
not been fully elucidated. 
Azoles 
The imidazoles clotrimazole, miconazole and keto- 
conazole, and the newer triazoles fluconazole and 
itraconazole, are the principal members of this class. 
Their target is also the plasma membrane, but mainly 
through inhibition of ergosterol biosynthesis. The 
triazoles inhibit cytochrome P-450-dependent 14-alpha 
demethylation of lanosterol, the precursor of ergosterol. 
The production of this enzyme is regulated by the 
ERG11 gene. 
Table 2. Antifungal drug MIC breakpoints* and their interpretation 
Organism Antifungal 
MIC Category (mg/L) 
Sensitive dose- 
Sensitive dependent Resistant 
Candida spp. 
Cryptococcus neoformans 
Fluconazole 
ltraconazole 
Flucytosine 
Amphotericin 
Fluconazole 
FIucvtosine* 
<8 
~0.125 
54 
54 
>8 and ~32 
>0.125 and ~0.5 
>4 and ~16 
>4 and ~16 
232 
>0.5 
>I6 
>o.s 
216 
>I6 
Adapted from reference no. 33. *Breakpoints not established. 
No breakpoints provided for mold susceptibility or amB versus yeasts. 
candidiasis6 especially in infections that are not 
responding adequately to the agent of first choice, 
usually amB, or because of amB toxicity. More recently, 
there has been interest in combining 5FC with azoles 
to avoid nephrotoxicity. Flucytosine is rarely used 
alone because of the likelihood of development of 
resistance.7 
Allylamines 
These act by inhibiting squaline epoxidase, which is 
involved in the early stages of ergosterol biosynthesis. 
The principal member of this group is terbinafine, which 
is highly active against dermatophytes and has proved 
more effective than griseofulvin for this indication. Its 
potential role in treating invasive fungal infections, in 
combination with other antifungals, is the subject of 
increasing interest. 
Echinocandins 
These represent a new class of antifungal agents with a 
novel mode of action by inhibition of beta-(1,3)-glucan 
synthase. Caspofungin is the first member of this group 
to become available for clinical use, having recently 
been licensed in the USA for salvage therapy of invasive 
aspergillosis. It is also effective in oropharyngeal 
candidiasis. 
DEFINITIONS OF DRUG RESISTANCE 
Because of the previous lack of a standardized 
methodology for the in vitro determination of antifungal 
drug susceptibility, clinical failure was often the sole, and 
inadequate, indicator of drug resistance. Following the 
development of the reference method for Cundidu,4 
breakpoints have been proposed for fluconazole, 
itraconazole and 5FC against yeasts which can be used 
to assess the likelihood of a clinical response to therapy 
on the basis of the MIC of the strain (Table 2). Using 
these criteria, most Candida spp. show either full or 
intermediate susceptibility to fluconazole and itracona- 
zole. These MIC categories can be interpreted to mean 
that a clinical response is very likely with susceptible 
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isolates or will be achieved with a higher dose when the 
MIC falls in the ‘dose-dependent’ category. The excep- 
tion is Candida krusei, because it is regarded as being 
inherently resistant to fluconazole. 
In vitro susceptibility testing may reveal that a 
clinical isolate is resistant to an antifungal even though 
the patient had never previously been treated with 
that drug; this is primary or intrinsic resistance. Fungi 
that may, with varying frequency, demonstrate primary 
resistance to the main antifungal drugs are listed in 
Table 3. 
Alternatively, a fungal strain may be observed to 
become resistant following a course of antifungal treat- 
ment, and this represents secondary or acquired resist- 
ance. To confirm this, it is necessary to test both the pre- 
and post-treatment isolates together, using the same 
susceptibility method. 
MECHANISMS OF ANTIFUNGAL DRUG 
RESISTANCE 
Azole resistance 
Azole resistance in Candida spp. has now been the 
subject of detailed investigation and review.5s,g The 
principal mechanisms are as follows. 
Alterations in the target lanosterol demethylase 
This is due to mutation(s) in the ERG11 gene resulting 
in reduced affinity of the target for the azole. This 
mechanism appears to account, in part at least, for the 
intrinsic resistance of Candida krusei to fluconazole.1° 
Several point mutations have been documented when 
fluconazole-sensitive and -resistant isolates of Candida 
albicans have been investigated.ll Point mutations in 
the ERG11 gene have been reported in azole-resistant 
isolates.i2 Over-expression of lanosterol demethylase 
has been observed in Candida glabrata associated 
with resistance to both fluconazole and itraconazole, 
but this may be a less important mechanism overall.i3 
Alterations can occur due to mutations in other ERG 
genes, and may additionally be involved in resistance of 
Cryptococcus neoformans to azoles.14 
Table 3. Fungi that may be inherently resistant to the main antifungal agents 
Amphotericin B 
Trichosporon beige/ii 
Candida lusitaniae 
Aspergillus terreus 
Scedosporium apiospermum 
Scopulariopsis dematiaceous 
Fusarium spp. 
Antifungal 
Fluconazole Flucy-tosine 
Candida dubliniensis Candida albicans 
Candida krusei Non-albicans Candida spp. 
Candida glabrata Cryptococcus neoformans 
Candida inconspicua Aspergillus spp. 
Candida norvegensis Dimorphic fungi 
Aspergillus spp. 
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An energy-dependent eflux mechanism 
This causes decreased intracellular accumulation of 
azoles. There are two types of efflux system that have 
been identified. These are the ATP binding cassette 
transporters (ABCTs) and major facilitators (MFs) 
respectively. The CDR genes are important members of 
the ABCT gene family. Over-expression of these genes 
is associated with resistance to azoles and also other 
antifungals. Over-expression of the MF gene MDRl 
(BEW) in Candida aZbicans15 is associated specifically 
with fluconazole resistance but not cross-resistance to 
other azoles. The development of azole resistance in 
clinical isolates of Candida spp. typically manifests itself 
following prolonged exposure to the drug and may 
involve several of the above resistance mechanisms 
concurrently.16 
Alterations in membrane sterols 
This may be another mechanism of azole resistance but 
it is poorly characterized and an uncommon occurrence 
to date. 
Polyene resistance 
Mechanisms of polyene resistance are less well studied 
than is the case for azoles. This is because amB resist- 
ance in clinical isolates is uncommon. One explanation 
for polyene resistance may be reduced ergosterol 
content in the fungal cell membrane. The ergosterol is 
replaced by other sterols that have reduced affinity for 
the polyene. The genetic mechanisms involved have not 
been comprehensively investigated. 
Flucytosine resistance 
Flucytosine resistance in Candida albicans or 
Cryptococcus neoformans is most commonly due to 
mutational changes in cytosine deaminase or uracilphos- 
phoribosyltransferase, which are involved in the 
pyrimidine salvage pathway. 
Table 4. Some risk factors, other than drug resistance, for 
failure of systemic antifungal therapy 
Risk factor Example 
Impaired drug absorption ltraconazole capsules used in 
neutropenic patients 
Accelerated drug metabolism Azoles by rifampicin 
Poor penetration into site of am6 in meningitis/brain 
infection infection 
Antagonism Azole-reducing effect of am6 
High fungal burden OPC in HIV-positive patients 
Foreign body is source of Central line in candidemia 
infection 
Persistent immunocompromise Hepatosplenic candidiasis 
Allylamine resistance 
Although resistance to terbinafine appears to be rare in 
clinical yeast isolates, it has been shown that some azole- 
resistant strains which over-express either CDRl or 
MDRl are cross-resistant to terbinafine.r7 
Echinocandin resistance 
Echinocandin resistance has not been investigated in 
any detail, because of insufficient clinical experience. 
The reduced activity of caspofungin against Cryptoco- 
ecus neoformans may be the result of lower affinity for 
the target glucan synthase enzyme.ls There is no 
evidence that strains of Candida spp. that are resistant 
to several azoles are cross-resistant to caspofungin, and 
this would suggest that efflux pumps do not impair the 
activity of this new drug. 
CHANGING EPIDEMIOLOGY OF FUNGAL 
INFECTIONS 
Candida spp., Aspergillus spp. and Cryptococcus 
neoformans are the principal causes of IFI, although 
there is an increasing number of infections due to 
‘emerging’ fungal pathogens, Fusarium and Scedo- 
sporium apiospermum being two notable examples. 
While Candida albicans is recognized as being the most 
frequent cause of candidiasis, there are recent reports 
that suggest a ‘pathogen shift’. To illustrate this. a com- 
parison between the Candida species documented in 
two studies of invasive candidiasis, published in 1993 and 
1998, reveals that the proportion of Candida albicans 
infections fell from over 70% to less than 60%, while the 
incidence of infections due to non-albicans Candida 
species almost doubled. 1g,20 In the latter study,20 in vitro 
antifungal susceptibility testing, performed according to 
the NCCLS recommendations4 showed that while 
isolates of Candida albicans, Candida parapsilosis and 
Candida tropicalis were almost universally susceptible 
to fluconazole and itraconazole, the resistance rates of 
Candida glabrata and Candida krusei were 8% and 
100% respectively. In neutropenic patients who receive 
azole prophylaxis, Candida glabrata and Candida krusei 
are the predominant yeast flora and the main cause of 
candidemia.21 
RISK FACTORS FOR FAILURE OF 
ANTIFUNGAL THERAPY 
When antifungal therapy fails, the possibility of either 
primary or acquired drug resistance of the organism has 
to be considered. However, there are other factors that 
relate to both the drug and the infected host which may 
also play a significant role, and these have to be taken 
into consideration (see Table 4). When treatment is 
administered orally, there is the possibility of impaired 
absorption and inadequate serum/tissue drug concen- 
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trations causing treatment failure. This has been reported 
when itraconazole capsules have been given to neutro- 
penic patients. A further problem of azole use is reduced 
efficacy due to accelerated metabolism when given 
together with other drugs that induce hepatic cyto- 
chrome P450 enzymes, the most common example 
being rifampicin. 
The pharmacokinetic profile of the drug also needs 
to be taken into consideration. AmB penetrates the 
blood-brain barrier poorly, while 5FC has excellent 
penetration; this may explain the improved outcome of 
cryptococcal meningitis when these two agents are used 
in combination compared to amB use alone. 
It is clear that the immune status of the infected host 
is critical to the outcome of an invasive fungal infection. 
Risk factors for acquired fluconazole resistance in HIV 
patients include CD4’ lymphocyte count of ~50 cells/ 
mm3, indicative of advanced AIDS, recurrent episodes 
of OPC, and prolonged prior exposure to azoles.22,23 In 
the case of neutropenic patients, invasive aspergillosis 
often fails to respond to antifungal agents in the face 
of continuing bone marrow failure. Patients who have 
made a recent recovery from neutropenia, and who 
develop the uncommon condition chronic hepatic 
candidiasis, are often unresponsive to antifungal drugs 
but may respond when they are combined with immuno- 
therapeutic agents. 24 The presence of vascular catheters 
is now recognized to be a major risk factor for the 
development of candidemia. Their presence also 
increases the likelihood of persistence of the infection 
despite adequate treatment.25 The development of 
Can&da biofilms coating the lumen of the catheter 
appears to enable the organism to persist and resist the 
action of antifungal drugs.26 
CLINICAL IMPACT OF ANTIFUNGAL DRUG 
RESISTANCE 
One of the earliest reports of acquired resistance to a 
systemic azole antifungal concerned a cohort of patients 
suffering from the rare inherited condition chronic 
mucocutaneous candidiasis.27 Twenty-one patients had 
received ketoconazole for prolonged courses of up to 2 
years. Two patients who relapsed on ketoconazole 
yielded Cundida isolates with MICs >lOO mg/L. Most 
cases of acquired resistance to azoles are HIV-positive 
patients being treated for OPC. Azoles quickly became 
established as the treatment of first choice, and fluco- 
nazole has been extensively used for this indication. 
Since the late 1980s there have been reports of both 
mycological and clinical failure with fluconazole, 
including cases where, despite an initial response to 
therapy, there was subsequently no response to escalating 
doses up to 800 mg/day, thereby suggesting the develop- 
ment of drug resistance. Typically, resistant strains of 
Cundidu ulbicuns are isolated from patients with un- 
responsive infections. Barchiesi et a12* matched the 
MICs of isolates with outcome of infection in AIDS 
patients and showed that there was a good correlation 
between in vitro resistance and failure of treatment. 
Typing of repeat isolates is important to confirm that the 
same strain is involved. Another explanation for clinical 
failure is a new infection with a fluconazole-resistant 
non-ulbicuns Cundidu species such as Cundidu glubrutu 
or Cundidu krusei. These species may alternatively only 
colonize the oropharynx or cause co-infection as a result 
of selective pressure associated with fluconazole use. 
In a study of deep-seated candidiasis due to 
Cundida albicuns or other Cundidu spp. in HIV-negative 
patients, MICs corresponded well with the outcome of 
treatment.29 However, when Rex et aP” studied 100 
bloodstream isolates stored from an earlier randomized 
treatment trial, they found that in 16 cases where the 
MIC indicated susceptibility, the infection failed to 
respond to fluconazole, while in four there was clinical 
success where the MIC was >32 mg/L. In the clinical 
trial, removal of central vascular catheters had a signifi- 
cant beneficial influence on the outcome of treatment,25 
and how these were managed may therefore have 
accounted for the incomplete correspondence between 
in vitro and clinical results. 
Fluconazole is available as an over-the-counter 
drug for treatment of vaginal candidiasis, and in the 
expectation of its widespread use there has been con- 
cern that resistant Cundidu ulbicuns would be reported 
in this setting. The first such report was in a 38-year-old 
woman who had persistent symptoms of vaginitis over a 
3-month period.31 Candida albicuns was isolated with an 
MIC to fluconazole of >40 mg/L and cross-resistance 
to itraconazole. Despite this report, the isolation of 
fluconazole-resistant Cundida albicans in HIV-negative 
individuals in the community is a rare event.32 
Correlations between itraconazole MICs and 
clinical outcome appear to be less good than for fluco- 
nazole, and this may be because of the bioavailabilty 
issues surrounding its oral administration.33 There are 
no relevant data on the intravenous formulation rele- 
vant to this aspect so far. 
Developing breakpoints for amB in order to 
separate susceptible and resistant Cundida spp. is made 
difficult by virtue of the fact that the MIC range within 
which these isolates fall is quite narrow. Variable results 
are obtained according to the method used. Generally, 
however, higher MICs correspond with poorer response 
to treatment. For example, Powderly et aP4 studied 26 
cases of candidemia in BMT patients and found that the 
incidence of fatal infection was significantly greater 
where the MIC of the isolate was >0.8 mg/L. 
In a study of cryptococcal meningitis35 in which 
fluconazole was given, either alone or in combination 
with 5FC, there was no correlation between response to 
fluconazole and MIC using the reference method; how- 
ever, when a modified MIC method was used, it was 
found that treatment failure was significantly associated 
with higher MICs. No correlation was found between 
MIC and response to 5FC. The situation is much less 
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clear for molds. Generally, there is no standardized 
method for MIC determination that has been clinically 
validated, although the NCCLS has proposed a broth 
microdilution method.36 In vitro resistance in A. 
jkmigatus appears to be rare, but when reported it 
has been shown that in vitro and in vivo findings 
correspond.37 
susceptibility testing of yeasts: approved standard. NCCLS 
document M27-A. Wayne PA: NCCLS, 1997. 
5. Ghannoum MA, Rice LB. Antifungal agents: mode of 
action, mechanisms of resistance, and correlation of these 
mechanisms with bacterial resistance. Clin Microbial Rev 
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CONCLUSION AND FUTURE PERSPECTIVES 
Over the past decade there has been a considerable 
increase in our knowledge of the mechanisms by which 
fungi can develop resistance to commonly used systemic 
antifungal drugs. With the help of the NCCLS method 
of in vitro susceptibility testing, it has become possible 
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predicting the likely clinical response in infections due 
to the most frequently pathogenic Candida spp. In vitro 
resistance will often reliably predict clinical failure, 
whereas susceptibility may not reliably predict clinical 
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itself will often play an important role in determining 
outcome, and these need to be included in the clinical 
assessment of the patient. 
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